Discover the full directors' dealings record of Thorne Healthtech, Inc., a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Thorne Healthtech, Inc. has published 36 public disclosures. The latest transaction was filed on 6 June 2022 (Attribution). Among the most active insiders: Varma Saloni S.. The full history is accessible without an account.
25 of 36 declarations
Thorne HealthTech, Inc. is a United States-based health and wellness company listed on the NASDAQ under the ticker THRN. For investors, the company sits at the intersection of consumer health, preventive care, personalized nutrition, and data-enabled wellness solutions. Its business model combines branded supplements, practitioner-led distribution, testing capabilities, and science-driven products aimed at consumers, health professionals, and corporate wellness use cases. ([thorne.com](https://www.thorne.com/press-releases/thorne-merges-with-onegevity-announces-new-parent-company-thorne-healthtech%3Fsrsltid%3DAfmBOop9VXyjJhNdSo4EQQvaHB2Y0vWNqqkPPl7lvlEt3rOs6TpX0YsP?utm_source=openai)) Thorne says its roots date back to 1984, giving the brand a long operating history in nutritional supplements and wellness products. A key strategic milestone came in 2010, when Paul Jacobson and his team acquired Thorne Research. In 2018, the company co-founded Onegevity to broaden its capabilities into health intelligence, personalization, and multi-omic data. More recently, in December 2023, Thorne announced the launch of Thorne Ventures and a reorganization into two units: Thorne, focused on supplements and testing, and Thorne Ventures, focused on innovation and the next generation of scientific wellness. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1844280/000095017023011358/thrn-20221231.htm?utm_source=openai)) Operationally, Thorne develops and sells clinically informed nutritional supplements, daily wellness essentials, probiotics, digestive health products, immune support formulas, cognitive health products, and performance-oriented solutions. The company emphasizes ingredient quality, rigorous manufacturing standards, in-house laboratory testing, third-party certifications, and collaborations with clinical researchers. Its proposition is not just product breadth, but scientific credibility and a personalized approach to health optimization. ([thorne.com](https://www.thorne.com/?utm_source=openai)) Thorne’s competitive positioning is built around trust and practitioner influence. In its 2022 annual report, the company disclosed a network of more than 47,000 health professionals, including physicians, dietitians, pharmacists, chiropractors, nutritionists, trainers, and other accredited practitioners. That distribution model is significant in a crowded supplements market, where differentiation typically depends on clinical reputation, brand quality, formulation integrity, and the ability to convert professional endorsement into repeat demand. Thorne’s brand is therefore closer to a premium science-led platform than a mass-market commodity supplement seller. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1844280/000095017023011358/thrn-20221231.htm?utm_source=openai)) Geographically, the company is headquartered in New York, United States, and primarily operates in the U.S., while also serving international markets through selected channels. Recent strategic developments include the February 2023 acquisition of PreCon Health to strengthen its brain-health portfolio, earlier transactions involving Nutrativa and Drawbridge Health, and the completion of L Catterton’s acquisition of Thorne HealthTech in 2023. For investors monitoring SEC Form 4 insider transactions, Thorne remains notable as a NASDAQ-listed health-tech and consumer wellness company with a science-driven identity, a premium brand position, and a growth strategy shaped by innovation, data, and selective M&A. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001844280/000095017023001743/thrn-ex99_1.htm?utm_source=openai))